Pediatric Academic Societies (PAS) 2021 Virtual Meeting

Dupilumab an alternative for children with severe AD

Audrey Abella, 20210519100000

The addition of the monoclonal antibody dupilumab to a standard topical corticosteroid (TCS) regimen led to significant improvements in scoring AD (SCORAD*) and its components, as well as EASI** scores, in children with severe atopic dermatitis (AD), according to data from the phase III LIBERTY AD PEDS trial presented at PAS 2021.

Delayed cord clamping may increase Hb levels in VLBW infants

Elaine Soliven, 20210519000000

Very low birth weight (VLBW) infants who received delayed cord clamping (DCC) for 45 seconds had a significantly higher haemoglobin (Hb) level than those who received immediate cord clamping (ICC), according to a study presented at PAS 2021.

Lumasiran shows therapeutic potential for primary hyperoxaluria type 1

Audrey Abella, 20210517100000

The RNAi* therapeutic agent lumasiran demonstrated favourable clinical outcomes for primary hyperoxaluria type 1 (PH1) in both paediatric and adult patients, according to the results of the phase III ILLUMINATE-A and ILLUMINATE-B trials presented at PAS 2021.

Secukinumab shows sustained improvement in paediatric psoriasis

Elaine Soliven, 20210516000000

Treatment with either low-dose (LD) or high-dose (HD) secukinumab showed continued improvement in PASI* and IGA** responses up to 24 weeks in children and adolescents with moderate-to-severe plaque psoriasis, according to updated results of a trial presented at PAS 2021.